NORWOOD, Mass., Nov. 29, 2016 /PRNewswire/ -- Entrinsic Health Solutions, Inc., an innovative health sciences company today announced the publication of results from research at the University of Florida using enterade® Advanced Oncology (AO) formulation titled, "An amino acid-based oral rehydration solution (AA-ORS) enhanced intestinal epithelial proliferation in mice exposed to radiation." The full article can be found in the 23 November, 2016 issue of Nature Scientific Reports at www.nature.com/articles/srep37220. The article is also available in the News & Media section of the Entrinsic Health Solutions website at www.entrinsichealth.com.
Through backing from the National Space Biomedical Research Institute (NSBRI), a NASA-funded consortium, the study in mice investigated the mechanism responsible for better absorption of electrolytes and nutrients with enterade® AO following radiation exposure. It was hypothesized that increased villus height induced by enterade is involved in increased electrolyte and nutrient absorption following irradiation. To study how enterade increases the absorptive surface area by increasing villus height, researchers at the University of Florida, Department of Radiation Oncology, investigated increased proliferation and the related mechanism both in the presence and absence of enterade® AO following radiation exposure. The study found that enterade® AO increased Lgr5+ stem cells; increased proliferation markers, such as p-Erk; and decreased apoptosis markers, such as cleaved caspase-3. This study shows that in situ stem cells and the intestinal epithelial cell proliferation induced by the amino acid combination in enterade® AO increased electrolyte and nutrient absorption by increasing villus height that comprised of mature, differentiated epithelial cells with increased functional capability to absorb electrolytes and nutrients.
Detailed results of the study showed that enterade® AO:
Increased crypt count and villus length in intestinal tissue from irradiated mice
Promoted intestinal epithelial cell migration
Increased Na+ and Cl- absorption
Increased glucose-stimulated Na+ absorption
"This study further validates the effectiveness of enterade® AO in the management of gastrointestinal side-effects as a result of cancer treatment," said Stephen Gatto, Chairman and Chief Executive Officer of Entrinsic Health Solutions. "Publication in Nature Scientific Reports is an achievement we share with Dr. Vidyasagar, UF Assistant Professor and the remarkable scientists and clinical investigators who conducted this research within the Department of Radiation Oncology at University of Florida." Dr. Vidyasagar's work has applications beyond cancer patients, as the foundational science he and his team have developed with the use of specific and targeted amino acid combinations along with the Amino Acid Coupled Transport (A2CT) technology may hold the key to intercepting diseases such as diabetes, wound healing, cognition, asthma and cystic fibrosis. We are excited and continue to believe Dr. Vidyasagar has opened up an area of science with extraordinary potential. Mr. Gatto went on to say, "We also want to acknowledge and express our gratitude to the NSBRI for their significant contribution to this research."
"We are thrilled with the demonstrated efficacy of enterade® AO in this radiation model because this simple and safe solution could potentially protect astronauts from the harmful effects of radiation during space exploration," said Dr. Dorit Donoviel, Deputy Chief Scientist of the NSBRI.
For nearly 20 years, Dr. Sadasivan Vidyasagar has studied new solutions for effectively treating and preventing dehydration and diarrhea associated with disease and infection. Because of his research finding that using concentrated sugar and salt solutions for hydration was not optimal and sometimes could make the situation worse, Dr. Vidyasager developed the technology in enterade® AO which does not contain any sugar. Furthermore, this research not only applies to patients being treated for cancer, but also within the space program for the hazards of radiation exposure, the number one health risk facing humans in deep space. Dr. Vidyasagar is Chief Scientific Officer and Co-founder of Entrinsic Health Solutions.
About enterade® AO
enterade® AO is a medical food for the dietary management of gastrointestinal dysfunction, benefitting individuals suffering from occasional diarrhea, cramping, dehydration, nausea and malnutrition. enterade® AO has recently completed clinical trials that showed to effectively reduce the negative side effects of chemotherapy and radiation treatment and restore healthy GI function for numerous conditions. enterade® AO is an ideal solution for patients undergoing treatment for cancer as well as for those diagnosed with conditions such as IBD (Crohn's and colitis), IBS, celiac, etc.
Powered by proprietary Amino Acid-Coupled Transport Technology (A2CT™), enterade® AO does not contain sugar to help effectively address digestive discomforts for improved quality of life. enterade® AO helps rebuild damaged GI structure and provides a protective gastrointestinal lining barrier that supports healthy immune function.
Clinical studies with enterade® AO have shown the patented blend of amino acids and electrolytes offer better electrolyte and water absorption in contrast to glucose-based alternatives. The result is a whole-body hydration with fluid shifting into all three fluid compartments, essential to achieve healthy gut function with enhanced nutrient absorption and retention.
enterade® AO is the flagship product of Entrinsic Health Solutions and was used in the original research partially sponsored by NASA and conducted by scientists and physicians at University of Florida. Entrinsic Health Solutions has partnered with 21st Century Oncology, a premier provider of radiation therapy and integrated cancer treatments, to confirm the efficacy of enterade® AO in oncology patients.
To learn more about enterade® AO, please visit www.enterade.com
About Entrinsic Health Solutions
Entrinsic Health Solutions, Inc., is an innovative health sciences company dedicated to the development and commercialization of amino acid based medical foods to address critical digestive health, nutrition and hydration related health issues. The Company's proprietary Amino Acid Coupled Transport (A2CT) Technology platform leverages gold-standard science and game-changing amino acid technology to address critical digestive- and hydration-related health issues. A2CT technology uses select amino acids to facilitate active transport of electrolytes throughout the body, which delivers rapid hydration, decreased gut permeability and improved nutrient absorption, supporting long-term digestive health. The Company's first commercial product, enterade® AO, is a first-in-class amino acid based medical food beverage that hydrates, rebuilds, and protects the gut lining and helps manage side effects from cancer treatments as well as occasional diarrhea, cramping, dehydration, nausea and malnutrition. The Company is involved in several on-going clinical trials designed to test the efficacy of the A2CT Technology for oncology and digestive health applications.
To learn more about Entrinsic Health Solutions, please visit entrinsichealth.com
Entrinsic Health Solutions
Last updated on: 29/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.